ArticleAntimicrobial agents and chemotherapy2013
Dried blood spot analysis suitable for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole.
Article in Antimicrobial agents and chemotherapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- Feasibility of dried blood spot collection for caffeine pharmacokinetic studies in microgravity: Insights from parabolic flight campaigns.British journal of clinical pharmacology · 2026Article
- Article
- Population pharmacokinetic model and limited sampling strategy for clozapine using plasma and dried blood spot samples.Therapeutic advances in psychopharmacology · 2022Article
- Review
- Clinical analysis of the effects of azole antifungal agents on the anticoagulant activity of warfarin.Medicine · 2020Article
- Combining lipidomics and machine learning to measure clinical lipids in dried blood spots.Metabolomics : Official journal of the Metabolomic Society · 2020Article
- Emerging trends in paper spray mass spectrometry: Microsampling, storage, direct analysis, and applications.Mass spectrometry reviews · 2020Review
- Assessment of disease specific immune responses in enteric diseases using dried blood spot (DBS).PloS one · 2019Article
- Article
- Therapeutic drug monitoring of tacrolimus and mycophenolic acid in outpatient renal transplant recipients using a volumetric dried blood spot sampling device.British journal of clinical pharmacology · 2018Article
- Invasive Candidiasis in the Elderly: Considerations for Drug Therapy.Drugs & aging · 2018Review
- Dried Blood Spot Methodology in Combination With Liquid Chromatography/Tandem Mass Spectrometry Facilitates the Monitoring of Teriflunomide.Therapeutic drug monitoring · 2016Article
- Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children.PloS one · 2016Article
- Therapeutic Drug Monitoring of Posaconazole: an Update.Current fungal infection reports · 2016Review
- Investigation of Saliva as an Alternative to Plasma Monitoring of Voriconazole.Clinical pharmacokinetics · 2015Article
- Therapeutic drug monitoring by dried blood spot: progress to date and future directions.Clinical pharmacokinetics · 2014Review
- Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.Clinical pharmacology and therapeutics · 2014Article
- Fundament and Prerequisites for the Application of an Antifungal TDM Service.Current fungal infection reportsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive aspergillosis and candidemia are important causes of morbidity and mortality in immunocompromised and critically ill patients. The triazoles voriconazole, fluconazole, and posaconazole are widely used for the treatment and prophylaxis of these fungal infections. Due to the variability of the pharmacokinetics of the triazoles among and within individual patients, therapeutic drug monitoring is important for optimizing the efficacy and safety of antifungal treatment. A dried blood spot (DBS) analysis was developed and was clinically validated for voriconazole, fluconazole, and posaconazole in 28 patients. Furthermore, a questionnaire was administered to evaluate the patients' opinions of the sampling method. The DBS analytical method showed linearity over the concentration range measured for all triazoles. Results for accuracy and precision were within accepted ranges; samples were stable at room temperature for at least 12 days; and different hematocrit values and blood spot volumes had no significant influence. The ratio of the drug concentration in DBS samples to that in plasma was 1.0 for voriconazole and fluconazole and 0.9 for posaconazole. Sixty percent of the patients preferred DBS analysis as a sampling method; 15% preferred venous blood sampling; and 25% had no preferred method. There was significantly less perception of pain with the DBS sampling method (P = 0.021). In conclusion, DBS analysis is a reliable alternative to venous blood sampling and can be used for therapeutic drug monitoring of voriconazole, fluconazole, and posaconazole. Patients were satisfied with DBS sampling and had less pain than with venous sampling. Most patients preferred DBS sampling to venous blood sampling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.